|
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura Clinical research trials and A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura. A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura clinical trial. Human subjects often obtain the finest healthcare possible for their A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura  A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura
For Condition: Immune thrombocytopenic purpura ( ITP ),HIV Infections
Status: Completed
Sponsor(s): Genentech ,
Synopsis: To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Dapsone at a constant dose level and only as a prophylaxis for Pneumocystis carinii pneumonia (PCP). - Zidovudine (AZT) at a constant dose for the 12 weeks of treatment, except if AZT-related toxicity is observed. Patients must have the following: - HIV seropositive (asymptomatic, AIDS-related complex, or AIDS). - HIV-associated immune thrombocytopenic purpura. - The ability to sign a written informed consent form, which must be obtained prior to treatment. - A willingness to abstain from all other experimental therapy for HIV infection during the entire study period. - Patients currently on zidovudine are not excluded. However, the zidovudine dose level must remain constant for 4 weeks prior to entry and for the 12 weeks of treatment, except if zidovudine related toxicity is observed. - A life expectancy of at least 3 months. Prior Medication: Allowed: - Dapsone at a constant dose for more than 2 weeks prior to study entry. - Zidovudine at a constant dose for 4 weeks prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions and symptoms are excluded: - Active serious opportunistic infection (excluding positive block cultures of Mycobacterium avium complex or Cytomegalovirus). - Malignancies other than Kaposi's sarcoma. - Tumor-associated edema. - Visceral Kaposi's sarcoma. - Significant neurologic, cardiac, or liver disease. Concurrent Medication: Excluded: - Ganciclovir (DHPG). Pyrimethamine. Clindamycin. Sulfadiazine. Folinic acid. Prednisone. Intravenous gamma globulin. Intravenous acyclovir. Interferon. Systemic corticosteroids. Non-steroidal anti-inflammatory drugs (NSAIDs). Known immunomodulatory agents. Dideoxycytosine. Dideoxyinosine. Nucleoside analogs (with the exception of zidovudine or topical acyclovir). Any experimental therapy. Patients with the following are excluded: - Active serious opportunistic infection (excluding positive block cultures of Mycobacterium avium complex or Cytomegalovirus). - Malignancies other than Kaposi's sarcoma. - Kaposi's sarcoma requiring therapy. - Tumor-associated edema. - Visceral Kaposi's sarcoma. - Significant neurologic, cardiac, or liver disease. - Conditions requiring excluded concomitant medications. - Herpes virus infection requiring intravenous acyclovir. Prior Medication: Excluded for a minimum of 4 weeks prior to study entry: - Chemotherapy. - Immunomodulatory agents. - Any experimental therapy. Prior Treatment: Excluded for a minimum of 4 weeks prior to study entry: - Radiation therapy. - Any experimental therapy.
Total Enrollment:
Location and Contact Information:
San Francisco Gen Hosp
San Francisco, California, 941102859
United States
Additional Information:
Study ID Numbers: 076A; D0177g
Study Start Date:
Record last reviewed: August 1991
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002250
Other Immune Thrombocytopenic Purpura ( Itp ) Studies:
1. A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura
Related Studies:
Other Immune thrombocytopenic purpura ( ITP ) Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura
|
|
|
|
|
|
|
|
